<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63559">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278471</url>
  </required_header>
  <id_info>
    <org_study_id>141583</org_study_id>
    <nct_id>NCT02278471</nct_id>
  </id_info>
  <brief_title>The SCCS Polypill Pilot Trial</brief_title>
  <official_title>The SCCS Polypill Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will examine the effect of the polypill on medication
      adherence, systolic blood pressure, and LDL cholesterol over a 12 month span.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess if a polypill-based approach to primary CVD
      prevention is feasible in a low socioeconomic status population. The study will assess
      whether a polypill approach is associated with better cardiovascular risk factor control
      compared with usual care.

      The polypill will be supplied as a compounded pill containing atorvastatin 10 mg, amlodipine
      2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg. The medications in the polypill
      have been extensively evaluated individually and in combination. Each of the medications in
      the polypill is approved by the United States Food and Drug Administration (FDA) and widely
      administered in the US for the treatment of and prevention of cardiovascular disease. The
      doses of each component medication included in the polypill are low, which should minimize
      the chance of any potential side-effects.

      In this study we assess medication adherence, systolic blood pressure, and LDL cholesterol
      over a 12 month span, in subjects taking the polypill versus subjects under usual care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>polypill versus usual care</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>12 months</time_frame>
    <description>polypill arm-evaluation via pill counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>12 months</time_frame>
    <description>Polypill versus usual care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>2 months</time_frame>
    <description>polypill versus usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>2 months</time_frame>
    <description>polypill-evaluation via pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>12 months</time_frame>
    <description>LC/MS/MS-based drug metabolite profile assay screen in the polypill arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>2 months</time_frame>
    <description>polypill versus usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Measurement of HOMA-IR using fasting glucose and insulin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory profile</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Plasma levels of IL-17, IFN-g, IL-6, IL-10, high sensitivity C-reactive protein, TNFa, IL-4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polypill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
Polypill will be taken once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)</intervention_name>
    <arm_group_label>Polypill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled at the SCCS site in Mobile, Alabama, obtain care at Franklin Primary Health
             Center, or live in the surrounding area.

          -  Aged 45-75 years

          -  Baseline systolic blood pressure ≥120 mm Hg.

        Exclusion Criteria:

          -  History of coronary heart disease or stroke

          -  History of cancer, except for basal cell skin cancer

          -  History of liver disease or laboratory evidence of hepatic dysfunction (an alanine
             aminotransferase level more than two times the upper limit of the normal range)

          -  Known renal disease, estimated creatinine clearance &lt; 60

          -  Current use of more than 2 anti-hypertensive medications

          -  LDL cholesterol ≥190 mg/dl

          -  Insulin-dependent diabetes

          -  Known intolerance to any of the components of the polypill

          -  Potassium &lt;3.4 or &gt;5.5 mEq/L

          -  Use of medications that interact with statins, including those affecting the
             cytochrome P450 system

          -  Current use of diuretics for indications other than hypertension

          -  Comorbidities that might be expected to limit lifespan during the 12-month follow-up
             period

          -  Inability to provide consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Univeristy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy P Mitchell</last_name>
    <phone>251-436-7631</phone>
    <email>judy.mitchell@franklinprimary.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Franklin Primary Health Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Mitchell</last_name>
      <phone>251-436-7631</phone>
      <email>judy.mitchell@franklinprimary.org</email>
    </contact>
    <investigator>
      <last_name>Prince Uzoije, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>October 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Thomas Wang</investigator_full_name>
    <investigator_title>Director of the Division of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>combination pill</keyword>
  <keyword>polypill</keyword>
  <keyword>primary prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
